^
    CANCER:

    Thyroid Gland Medullary Carcinoma





    Show legend
    Group by Gene:
    Include preclinical:

    cabozantinib capsule
    		0
    Multi-tyrosine kinase inhibitor
    vandetanib
    cabozantinib tablet
    AMG 706
    selpercatinib
    pralsetinib
    SY-5007
    		1
    RET inhibitor
    EP0031
    BOS-172738
    RET inhibitor
    TAS0953 / HM06
    2
    DNA synthesis inhibitor
    dacarbazine
    3
    RANK ligand inhibitor
    denosumab
    4
    mTOR inhibitor, Multi-tyrosine kinase inhibitor
    everolimus + vandetanib
    5
    mTOR inhibitor
    everolimus
    6
    ALK inhibitor
    alectinib
    7
    PD1 inhibitor
    pembrolizumab
    8
    pan-RAF inhibitor, Multi-tyrosine kinase inhibitor
    sorafenib
    9
    RET inhibitor, Src kinase inhibitor
    TPX-0046
    10
    pan-RAF inhibitor, CXCL12 inhibitor, Farnesyl transferase inhibitor, Multi-tyrosine kinase inhibitor
    sorafenib + tipifarnib
    11
    VEGFR inhibitor, PDGFR inhibitor, c-KIT inhibitor
    sunitinib
    12
    VEGFR-2 inhibitor, PI3K inhibitor, mTOR inhibitor, BRAF inhibitor
    RTB101 + RAF265
    13
    MEK inhibitor
    CI-1040
    14
    Immunotherapy
    Immunotherapy
    15
    VEGFR-2 inhibitor, BRAF inhibitor
    RAF265
    16
    FGFR inhibitor, VEGFR inhibitor, RET inhibitor, c-KIT inhibitor, PDGFR α antagonist
    lenvatinib
    No biomarker
    RET M918T
    RET mutation
    RET L629P
    RET V804*
    RET C634*
    RET C634R
    RET V804M
    RET V804L
    RET positive
    RET C620R
    RET C618R
    RET C634F
    RET D631_R635delinsG
    RET V637R
    RET exon 11 deletion
    RET V804M + M918T
    RET Y900_S904delinsP
    RET V804M + RET M918T + RET G810 + RET Y806
    RET C634W
    RET C634Y
    KRAS mutation
    NRAS mutation
    KRAS G12R
    ATM S978fs*12
    ATM L804fs*4
    NF1 mutation
    CCDC6-ALK fusion
    TMB-H
    RET M918T + ATM L804fs*4 + ATM S978fs*12
    RAS mutation
    BRAF mutation
    BRAF V600E
    PTEN mutation